CAPR CAPRICOR THERAPEUTICS, INC.
FY2025 10-K
CAPRICOR THERAPEUTICS, INC. (CAPR) filed its fiscal year 2025 10-K annual report with the SEC on Mar 17, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: development and manufacturing of cell-based therapies and exosome technologies, focus on Deramiocel for commercial and clinical use
- • New emphasis on potential vaccine candidates using exosome technologies with unique manufacturing and regulatory challenges highlighted
Management Discussion & Analysis
- • No specific revenue figures or YoY changes disclosed in provided text
- • No profitability, margin, or segment performance metrics mentioned
Risk Factors
- • Regulatory risk: FDA Complete Response Letter in July 2025 for Deramiocel BLA, requiring additional Phase 3 HOPE-3 trial data, new PDUFA date August 22, 2026
- • Geopolitical/macro risk: Exposure to U.S. public health policy through NIH/NIAID collaboration on StealthX™ vaccine under Project NextGen initiative
Get deeper insights on CAPRICOR THERAPEUTICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.